Is denying RAI ablation in the low risk differentiated thyroid cancer patients justified?

被引：0
|
作者：
Agrawal, K. [1 ]
Kashyap, R. [1 ]
Bhattacharya, A. [1 ]
Mittal, B. R. [1 ]
机构：
[1] PGIMER, Chandigarh, India
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2011年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S223 / S224
页数：2
相关论文
共 50 条
  • [21] Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer
    Caglar, Meltem
    Bozkurt, Fani M.
    Akca, Ceren Kapulu
    Vargol, Sezen Elhan
    Bayraktar, Miyase
    Ugur, Omer
    Karaagaoglu, Ergun
    NUCLEAR MEDICINE COMMUNICATIONS, 2012, 33 (03) : 268 - 274
  • [22] Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients
    Castagna, Maria Grazia
    Cevenini, Gabriele
    Theodoropoulou, Alexandra
    Maino, Fabio
    Memmo, Silvia
    Claudia, Cipri
    Belardini, Valentina
    Brianzoni, Ernesto
    Pacini, Furio
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2013, 169 (01) : 23 - 29
  • [23] Effectiveness of lowradioiodine administered activity in patients with low risk differentiated thyroid cancer
    Yeddes, I., Jr.
    Ben Ghachem, T.
    Meddeb, I.
    Limam, K.
    Somaii, M.
    Slim, I.
    Ben Slimene, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S373 - S373
  • [24] Parathyroid Changes After RAI in Patients With Differentiated Thyroid Carcinoma
    Xiao, Liu
    Zhang, Wenjie
    Zhu, Hongmei
    Wang, Yueqi
    Liu, Bin
    Huang, Rui
    Li, Lin
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [25] Our first experience with low dose radioiodine ablation Therapy in low risk patients with differentiated thyroid carcinoma
    Rajkovaca, Z.
    Mijatovic, J.
    Skrobic, M.
    Mikac, G.
    Vuleta, G.
    Matavulj, A.
    Kovacevic, P.
    Ponorac, N.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S356 - S356
  • [26] Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients
    Krajewska, Jolanta
    Jarzab, Michal
    Czarniecka, Agnieszka
    Roskosz, Jozef
    Kukulska, Aleksandra
    Handkiewicz-Junak, Daria
    Puch, Zbigniew
    Wygoda, Zbigniew
    Paliczka-Cieslik, Ewa
    Kropinska, Aleksandra
    Gubala, Elzbieta
    Jurecka-Lubieniecka, Beata
    Jarzab, Barbara
    ENDOKRYNOLOGIA POLSKA, 2016, 67 (01) : 2 - 11
  • [27] Postoperative Radioiodine Ablation in Low-Risk Differentiated Thyroid Cancer: Outcomes of Patients Treated with Different Doses in a Single Center
    Orun, S.
    Soyluoglu, S.
    Korkmaz, U.
    Ustun, F.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S587 - S588
  • [28] Outcomes of radioactive iodine (RAI) ablation for differentiated thyroid cancer (DTC): no versus low versus high dose- The Alfred Hospital Experience
    Graf, Anneke
    Vereker, Melissa
    Serpell, Jonathan
    Topliss, Duncan J.
    CLINICAL ENDOCRINOLOGY, 2017, 86 : 34 - 34
  • [29] Fractionated dosage of radioiodine for the ablation of low-risk differentiated thyroid cancer has no impact on survival
    Wolinski, Kosma
    Czepczynski, Rafal
    Stangierski, Adam
    Trojanowski, Maciej
    Rewaj-Losyk, Magdalena
    Ziemnicka, Katarzyna
    Baczyk, Maciej
    Dyzmann-Sroka, Agnieszka
    Ruchala, Marek
    ENDOKRYNOLOGIA POLSKA, 2018, 69 (03) : 230 - 234
  • [30] Prospective Study Confirms that Radioiodine Remnant Ablation Is Not Necessary in Low-Risk Differentiated Thyroid Cancer
    Pacini, Furio
    EUROPEAN THYROID JOURNAL, 2016, 5 (01) : 7 - +
12345